Beijing Hospitals Authority Clinical medicine Development of special funding support (ZLRK202301)
[DOI] [PubMed] [Google Scholar] 179.Finn J.D., Smith A.R., Patel M.C., Shaw L., Youniss M.R., van Heteren J., Dirstine T., Ciullo C., Lescarbeau R., Seitzer J., Shah R.R., Shah A., Ling D., Growe J., Pink M., Rohde E., Wood K.M., Salomon W.E., Harrington W.F., Dombrowski C., Strapps W.R., Chang Y., Morrissey D.V
IGF-1 peptides are treated as unlicensed drugs
These GSHPEG liposomes (G-technology) have also demonstrated brain targeting as well as therapeutic efficacy in murine models of brain cancer (2B3-101
Springer International Publishing, Cham, pp 343352 Sloan G, Selvarajah D, Tesfaye S (2021) Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Side effects: retatrutide and tirzepatide compared They share the same gut-first adverse events this whole drug class is known for